FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4247450139> ?p ?o ?g. }

• W4247450139 endingPage "49" @default.
• W4247450139 startingPage "49" @default.
• W4247450139 abstract "Purpose/Objective: A multi-institutional trial was conducted by the RTOG to test the feasibility of performing a neurocognitive test battery consisting of 5 measures and a quality of life instrument in patients with brain metastases.Materials/Methods: Major eligibility requirements included: 1) histological proof of a primary malignancy, 2) measurable single or multiple brain metastases, 3) Zubrod performance status 0–1, 4) neurological function status 0–2, and 5) “certification” for administration of neurocognitive assessments. This certification process required either attendance at an RTOG neurocognitive assessment training workshop, or review of an instructional video, followed by submission of an audio of mock/simulated test sessions for central review. The test battery included the following measures: 1) Mini-Mental State Exam (MMSE), 2) Hopkins Verbal Learning Test (HVLT), 3) Verbal Fluency/Controlled Word Association Test (COWAT), 4) Ruff 2 and 7 test ( 2 & 7 ), 5) Trailmaking Test (TMT), and 6) Profile of Mood States Short Form (POMS-SF). The primary objective of this trial was to establish whether patients were able to complete this test battery. Compliance was defined as successful completion of a test measure based on available data, as data for all patients was not available at this time. The test battery was to be administered just prior to, at completion of, and at 1 month following whole brain radiation therapy to 37.5 Gy at 2.5 Gy per fraction once daily. Between November 2000 and August 2001, 59 patients were enrolled to the trial.Results: Patient characteristics included: 32% > 65 years; 44% performance status 0; 81% with multiple brain metastases. Patient compliance with the test battery at the three time points is summarized in the table below. Overall compliance was >90%. The most common causes of non-compliance were patient related factors (e.g. performance status or inability to understand test instructions) and not institutional error.Conclusions: Neurocognitive evaluation of patients with brain metastases in a multi-institutional and cooperative group setting appears feasible using the test battery and certification process employed in this study. This battery and certification process will be incorporated into future RTOG brain tumor trials. Updated analyses will be presented at the ASTRO meeting. Tabled 1MMSEHVLTCOWATRuff 2 & 7TMT-ATMT-BPOMS-SFPretreatment Forms Compliance (%)51/51(100)47/49 (94)49/50 (98)45/48 (94)49/50 (98)47/49 (96)49/51 (96)End of Treatment Compliance (%)40/42 (95)40/42 (95)40/42 (95)38/41 (93)42/43 (98)38/41 (93)38/41 (93)One Month Follow-Up Compliance (%)33/34 (97)27/31 (87)29/32 (91)23/29 (79)23/29 (79)23/29 (79)29/32 (91) Open table in a new tab Purpose/Objective: A multi-institutional trial was conducted by the RTOG to test the feasibility of performing a neurocognitive test battery consisting of 5 measures and a quality of life instrument in patients with brain metastases. Materials/Methods: Major eligibility requirements included: 1) histological proof of a primary malignancy, 2) measurable single or multiple brain metastases, 3) Zubrod performance status 0–1, 4) neurological function status 0–2, and 5) “certification” for administration of neurocognitive assessments. This certification process required either attendance at an RTOG neurocognitive assessment training workshop, or review of an instructional video, followed by submission of an audio of mock/simulated test sessions for central review. The test battery included the following measures: 1) Mini-Mental State Exam (MMSE), 2) Hopkins Verbal Learning Test (HVLT), 3) Verbal Fluency/Controlled Word Association Test (COWAT), 4) Ruff 2 and 7 test ( 2 & 7 ), 5) Trailmaking Test (TMT), and 6) Profile of Mood States Short Form (POMS-SF). The primary objective of this trial was to establish whether patients were able to complete this test battery. Compliance was defined as successful completion of a test measure based on available data, as data for all patients was not available at this time. The test battery was to be administered just prior to, at completion of, and at 1 month following whole brain radiation therapy to 37.5 Gy at 2.5 Gy per fraction once daily. Between November 2000 and August 2001, 59 patients were enrolled to the trial. Results: Patient characteristics included: 32% > 65 years; 44% performance status 0; 81% with multiple brain metastases. Patient compliance with the test battery at the three time points is summarized in the table below. Overall compliance was >90%. The most common causes of non-compliance were patient related factors (e.g. performance status or inability to understand test instructions) and not institutional error. Conclusions: Neurocognitive evaluation of patients with brain metastases in a multi-institutional and cooperative group setting appears feasible using the test battery and certification process employed in this study. This battery and certification process will be incorporated into future RTOG brain tumor trials. Updated analyses will be presented at the ASTRO meeting. Tabled 1MMSEHVLTCOWATRuff 2 & 7TMT-ATMT-BPOMS-SFPretreatment Forms Compliance (%)51/51(100)47/49 (94)49/50 (98)45/48 (94)49/50 (98)47/49 (96)49/51 (96)End of Treatment Compliance (%)40/42 (95)40/42 (95)40/42 (95)38/41 (93)42/43 (98)38/41 (93)38/41 (93)One Month Follow-Up Compliance (%)33/34 (97)27/31 (87)29/32 (91)23/29 (79)23/29 (79)23/29 (79)29/32 (91) Open table in a new tab" @default.
• W4247450139 created "2022-05-12" @default.
• W4247450139 creator A5026888001 @default.
• W4247450139 creator A5029810793 @default.
• W4247450139 creator A5038665172 @default.
• W4247450139 creator A5046927250 @default.
• W4247450139 creator A5048176134 @default.
• W4247450139 creator A5052233371 @default.
• W4247450139 creator A5058130022 @default.
• W4247450139 creator A5060155830 @default.
• W4247450139 creator A5082973021 @default.
• W4247450139 creator A5087295298 @default.
• W4247450139 date "2002-10-01" @default.
• W4247450139 modified "2023-10-17" @default.
• W4247450139 title "Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of radiation therapy oncology group (RTOG) trial BR-0018" @default.
• W4247450139 doi "https://doi.org/10.1016/s0360-3016(02)03140-1" @default.
• W4247450139 hasPublicationYear "2002" @default.
• W4247450139 type Work @default.
• W4247450139 citedByCount "1" @default.
• W4247450139 crossrefType "journal-article" @default.
• W4247450139 hasAuthorship W4247450139A5026888001 @default.
• W4247450139 hasAuthorship W4247450139A5029810793 @default.
• W4247450139 hasAuthorship W4247450139A5038665172 @default.
• W4247450139 hasAuthorship W4247450139A5046927250 @default.
• W4247450139 hasAuthorship W4247450139A5048176134 @default.
• W4247450139 hasAuthorship W4247450139A5052233371 @default.
• W4247450139 hasAuthorship W4247450139A5058130022 @default.
• W4247450139 hasAuthorship W4247450139A5060155830 @default.
• W4247450139 hasAuthorship W4247450139A5082973021 @default.
• W4247450139 hasAuthorship W4247450139A5087295298 @default.
• W4247450139 hasConcept C118552586 @default.
• W4247450139 hasConcept C126322002 @default.
• W4247450139 hasConcept C151730666 @default.
• W4247450139 hasConcept C162324750 @default.
• W4247450139 hasConcept C169900460 @default.
• W4247450139 hasConcept C172467417 @default.
• W4247450139 hasConcept C1862650 @default.
• W4247450139 hasConcept C2777267654 @default.
• W4247450139 hasConcept C2778173179 @default.
• W4247450139 hasConcept C2780733359 @default.
• W4247450139 hasConcept C50522688 @default.
• W4247450139 hasConcept C70410870 @default.
• W4247450139 hasConcept C71924100 @default.
• W4247450139 hasConcept C86803240 @default.
• W4247450139 hasConceptScore W4247450139C118552586 @default.
• W4247450139 hasConceptScore W4247450139C126322002 @default.
• W4247450139 hasConceptScore W4247450139C151730666 @default.
• W4247450139 hasConceptScore W4247450139C162324750 @default.
• W4247450139 hasConceptScore W4247450139C169900460 @default.
• W4247450139 hasConceptScore W4247450139C172467417 @default.
• W4247450139 hasConceptScore W4247450139C1862650 @default.
• W4247450139 hasConceptScore W4247450139C2777267654 @default.
• W4247450139 hasConceptScore W4247450139C2778173179 @default.
• W4247450139 hasConceptScore W4247450139C2780733359 @default.
• W4247450139 hasConceptScore W4247450139C50522688 @default.
• W4247450139 hasConceptScore W4247450139C70410870 @default.
• W4247450139 hasConceptScore W4247450139C71924100 @default.
• W4247450139 hasConceptScore W4247450139C86803240 @default.
• W4247450139 hasIssue "2" @default.
• W4247450139 hasLocation W42474501391 @default.
• W4247450139 hasOpenAccess W4247450139 @default.
• W4247450139 hasPrimaryLocation W42474501391 @default.
• W4247450139 hasRelatedWork W192878447 @default.
• W4247450139 hasRelatedWork W1980463606 @default.
• W4247450139 hasRelatedWork W2408105773 @default.
• W4247450139 hasRelatedWork W2415632367 @default.
• W4247450139 hasRelatedWork W2567910647 @default.
• W4247450139 hasRelatedWork W2588847688 @default.
• W4247450139 hasRelatedWork W31819717 @default.
• W4247450139 hasRelatedWork W3205364021 @default.
• W4247450139 hasRelatedWork W4210524002 @default.
• W4247450139 hasRelatedWork W57936719 @default.
• W4247450139 hasVolume "54" @default.
• W4247450139 isParatext "false" @default.
• W4247450139 isRetracted "false" @default.
• W4247450139 workType "article" @default.